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Abstract
Background: Lassa fever is a neglected tropical disease with significant impact on the health care system, society,
and economy of Western and Central African nations where it is endemic. Treatment of acute Lassa fever infections
has successfully utilized intravenous administration of ribavirin, a nucleotide analogue drug, but this is not an
approved use; efficacy of oral administration has not been demonstrated. To date, several potential new vaccine
platforms have been explored, but none have progressed toward clinical trials and commercialization. Therefore, the
development of a robust vaccine platform that could be generated in sufficient quantities and at a low cost per dose
could herald a subcontinent-wide vaccination program. This would move Lassa endemic areas toward the control
and reduction of major outbreaks and endemic infections. To this end, we have employed efficient mammalian
expression systems to generate a Lassa virus (LASV)-like particle (VLP)-based modular vaccine platform.
Results: A mammalian expression system that generated large quantities of LASV VLP in human cells at small scale
settings was developed. These VLP contained the major immunological determinants of the virus: glycoprotein
complex, nucleoprotein, and Z matrix protein, with known post-translational modifications. The viral proteins
packaged into LASV VLP were characterized, including glycosylation profiles of glycoprotein subunits GP1 and GP2,
and structural compartmentalization of each polypeptide. The host cell protein component of LASV VLP was also
partially analyzed, namely glycoprotein incorporation, though the identity of these proteins remain unknown. All
combinations of LASV Z, GPC, and NP proteins that generated VLP did not incorporate host cell ribosomes, a
known component of native arenaviral particles, despite detection of small RNA species packaged into
pseudoparticles. Although VLP did not contain the same host cell components as the native virion, electron
microscopy analysis demonstrated that LASV VLP appeared structurally similar to native virions, with pleiomorphic
distribution in size and shape. LASV VLP that displayed GPC or GPC+NP were immunogenic in mice, and
generated a significant IgG response to individual viral proteins over the course of three immunizations, in the
absence of adjuvants. Furthermore, sera from convalescent Lassa fever patients recognized VLP in ELISA format,
thus affirming the presence of native epitopes displayed by the recombinant pseudoparticles.
Conclusions: These results established that modular LASV VLP can be generated displaying high levels of
immunogenic viral proteins, and that small laboratory scale mammalian expression systems are capable of
producing multi-milligram quantities of pseudoparticles. These VLP are structurally and morphologically similar to
native LASV virions, but lack replicative functions, and thus can be safely generated in low biosafety level settings.
LASV VLP were immunogenic in mice in the absence of adjuvants, with mature IgG responses developing within a
few weeks after the first immunization. These studies highlight the relevance of a VLP platform for designing an
optimal vaccine candidate against Lassa hemorrhagic fever, and warrant further investigation in lethal challenge
animal models to establish their protective potential.
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Lassa virus, a member of the Arenaviridae family, is the
etiologic agent of Lassa fever, which is an acute and
often fatal illness endemic to West Africa. There are an
estimated 300,000 - 500,000 cases of Lassa fever each
year [1-3], with a mortality rate of 15%-20% for hospita-
lized patients and as high as 50% during epidemics [4,5].
Presently, there is no licensed vaccine or immunother-
apy available for preventing or treating this disease.
Although the antiviral drug Ribavirin is somewhat bene-
ficial, it must be administered at an early stage of infec-
tion to successfully alter disease outcome, thereby
limiting its utility [6]. Furthermore, there is no commer-
cially available Lassa fever diagnostic assay, which ham-
pers early detection and rapid implementation of
existing treatment regimens (e.g. Ribavirin administra-
tion). The severity of the disease, ability to be trans-
mitted by aerosol, and lack of a vaccine or therapeutic
drug led to its classification as a National Institutes of
Allergy and Infectious Diseases (NIAID) Category A
pathogen and biosafety level-4 (BSL-4) agent.
The LASV genome is comprised of two ambisense,
single-stranded RNA molecules designated small (S) and
large (L) [7]. Two genes on the S segment encode the
nucleoprotein (NP) and two envelope glycoproteins
(GP1 and GP2); whereas, the L segment encodes the
viral polymerase (L protein) and RING finger Z matrix
protein. GP1 and GP2 subunits result from post-transla-
tional cleavage of a precursor glycoprotein (GPC) by the
p r o t e a s eS K I - 1 / S 1 P[ 8 ] .G P 1s e r v e sap u t a t i v er o l ei n
receptor binding, while the structure of GP2 is consis-
tent with viral transmembrane fusion proteins [9]. NP is
an abundant virion protein that binds and protects the
viral RNA. The Z matrix protein associates with GP2
and NP during viral biogenesis, but alone is sufficient to
mediate formation and release of viral particles from
infected/transfected cells [10].
Results
LASV gene expression and incorporation in VLP
Transient transfection of HEK-293T/17 cells with LASV
GPC, NP, and Z gene constructs resulted in high level
expression of all proteins, including their known post-
translational processing. The glycoprotein complex
(GPC) was detected as a 75 kDa polyprotein precursor
in transfected cell extracts, and in VLP preparations
(Figure 1 Ai,A ii,B i lanes 2 - 9; Additional file 1: Figure
S1 Ci lane 4). Similarly, the proteolytically processed
GP1 and GP2 subunits were detected in cell extracts
(Additional file 1: Figure S1 Ci lane 4) and in purified
VLP (Figure 1 Ai,A ii,B i l a n e s2-9 )a s4 2a n d3 8k D a
glycosylated species, respectively. In VLP cell culture
supernatants cleared by ultracentrifugation, the soluble
LASV GP1 isoform previously described in this expres-
sion system was also detected at high levels (Figure 1
Ai, lane 1) [11,12]. Nucleoprotein (NP) was mainly
detected as a 60 kDa species with smaller fragments
identified, namely a 24 kDa protein corresponding to a
previously described proteolysis product generated dur-
ing LASV infection in vitro (Figure 1 Aiii lanes 2 - 9;
Additional file 1: Figure S1 Ci, lane 1), [13-16]. The
nucleoprotein was largely absent from the extracellular
milieu (Additional file 1: Figure S1 Cii,l a n e1 )u n l e s s
the Z matrix protein was co-expressed (Figure 1 Aiii,
Aiv, lanes 2 - 9). Nucleoprotein that was not associated
with VLP was present in the input fraction, as assessed
by corresponding lack of GP2 and Z matrix protein
detection (Figure 1 Aiii, lane 1). The Z matrix protein
was detected in cell extracts (Additional file 1: Figure S1
Ci, lane 2) and in VLP preparations, as a 12 kDa protein
(Figure 1 Aiv,B ii, lanes 2 - 9). An N-terminal 6X-HIS
tagged Z protein gene variant starting at amino acid
position +3 that disrupted the known mirystoylation
domain also expressed at high levels, but failed to gener-
ate VLPs, as determined by lack of detection of the pro-
tein in cell culture supernatants (Additional file 1:
Figure S1 Ci, ii, lane 3).
To determine if tagged arenaviral gene sequences ben-
efitted overall expression levels and incorporation into
VLP a series of matrix experiments were performed that
combined native and/or 6X-HIS or FLAG epitope tags.
Only the addition of a 6X-HIS tag to the C-terminus of
the Z gene did not affect its expression and incorpora-
tion into VLP (Additional file 2: Figure S2). The addi-
tion of C-terminal tags to GPC or NP resulted in lower
expression levels and resulting incorporation into VLP.
In some cases these tags led to unexpected and unto-
ward proteolytic processing (Additional file 2: Figure S2,
lane 6).
Large scale generation of LASV VLP
Generation of LASV VLP from 6 well plates through 15
cm cell culture dishes resulted in linear volumetric
increase in particle yields (~100 μg/35 mm well; ~2 mg/
15 cm dish). Production of VLP for biochemical charac-
terization and in vivo studies was performed in multiple
15 cm culture dishes, which routinely yielded an average
of 2 mg of total VLP protein per dish, as determined by
Micro BCA and SDS-PAGE. VLP generated from
expression of LASV Z, GPC, and NP gene constructs
resulted in particles with higher densities than those
produced by expression of Z and GPC alone, as assessed
by relative levels of each viral protein throughout the
sucrose density spectrum (Figure 1A,B, lanes 2 - 9). The
majority of Z+GPC+NP VLP sedimented between 30
and 60% sucrose (Figure 1Ai - iv, lanes 4 - 8), whereas
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Page 2 of 19Figure 1 Purification of HEK-293T/17 generated LASV VLP by sucrose gradient sedimentation and detection of GP1, GP2, NP, and Z
proteins in fractions by western blot analysis. LASV VLP were precipitated with PEG-6000/NaCl and concentrated by ultracentrifugation.
Pellets were resuspended in 500 μL of TNE or PBS, overlayed on discontinuous 20 - 60% sucrose gradients, and sedimented by
ultracentrifugation. Eight fractions of 500 μL each were collected from sucrose gradients. Ten μL from each fraction were separated on
denaturing 10% NuPAGE gels, blotted and probed with LASV protein-specific mAbs. LASV VLP packaging Z+GPC+NP (A) and Z+GPC (B) were
analyzed for distribution of GP1 (Ai,B i), GP2 (Aii), NP (Aiii), and Z (Aiv,B ii) throughout the gradient spectrum. Fraction 1 contained input
supernatant (S) loaded onto gradients. Fractions 2 through 8 were from 20 - 60% sucrose gradients. Lane 9 contained insoluble material that
pelleted through 60% sucrose (P). The size of each protein in kDa is indicated to the right of each blot (unprocessed GPC: 75 kDa, GP1: 42 kDa,
GP2: 38 kDa, NP: 60 kDa, and Z: 12 kDa).
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Page 3 of 19Z+GPC VLP were present in ~25 - 40% sucrose frac-
tions (Figure 1Bi, ii, lanes 3 - 5). Surprisingly, Z+GPC
VLP sedimenting through 30 - 60% sucrose contained
progressively lower levels of Z matrix protein (Figure
1Bii, lanes 6 - 8) than counterparts containing both NP
(Figure 1Aiv, lanes 6 - 8) and Z. In both Z+GPC and Z
+GPC+NP VLP preparations a considerable insoluble
fraction pelleted through 60% sucrose, and could only
be dissolved in reducing SDS-PAGE buffer (Figure 1Ai -
iv,1 Bi - ii, lane 9 [P]).
Effects of LASV gene expression on mammalian cell
morphology - cytotoxicity
Expression of LASV GPC or NP alone did not induce
significant morphological changes in 293T/17 cells
through 72 hours post-transfection when compared to
untransfected, mock transfected, or vector only trans-
fected cells, as assessed by light microscopy (Figure 2A,
B). By contrast, inclusion of Z matrix gene protein in
transfection experiments resulted in significant morpho-
logical changes marked by elongation of cells by 24
hours and significant detachment from the Poly-D-
Lysine coated culture surface by 48 hours, resulting in
large areas of monolayer breakdown (Figure 2C). Cellu-
lar cytotoxicity was measured by MTT assays, and chro-
mosomal DNA fragmentation analysis was employed to
determine gross apoptotic or necrotic cell death
mechanisms. Triplicate MTT experiments verified that
single LASV NP, GPC, and GPC-FLAG gene expression
did not result in significant cellular cytotoxicity when
compared to vector transfected and untransfected 293T/
17 cell controls (Additional file 3: Figure S3B, lanes 1 -
3 versus lanes 16, 17). The inclusion of LASV Z or
Z3’HIS in transfections experiments, alone or in combi-
nation with any other LASV gene constructs resulted in
significant levels of cytotoxicity, as measured by reduced
O.D. 562 levels in MTT assays (Additional file 3: Figure
S3, lanes 4 - 15), with p < 0.05 to p < 0.001, n = 3 for
each condition. Despite significant differences in MTT
assays among transfected LASV gene combinations,
TAE-agarose gel analysis showed lack of visible DNA
fragmentation after a 72 hour transfection (Additional
file 3: Figure S3A, lanes 4 - 17).
LASV VLP contain a multitude of cellular proteins in
addition to viral polypeptides
Analysis of sucrose gradient-purified LASV VLP by
SDS-PAGE and Coomassie BB-R250 staining revealed a
multitude of proteins in addition to the expected viral
polypeptides at ~ 40 kDa (GP1 and GP2), 60 kDa (NP),
and 12 kDa (Z) (Figure 3A, lanes 1 - 9). These additional
proteins are host cell derived polypeptides which range
from ~20 kDa to 200 kDa in size. Supernatants of
mock or pcDNA3.1+:intA transfected cells do not yield
detectable levels of PEG-6000/NaCl and sucrose cushion
and/or gradient centrifugation-derived proteins, as deter-
mined by Micro BCA and SDS-PAGE analyses (data not
shown). Glycan analysis using a wide range of lectins
revealed that a significant number of non-viral proteins
incorporated into LASV VLP are glycoproteins (Figure 3B,
lanes 1 - 9). Lectin binding specificity was assessed by lack
of binding to LASV NP, GP1, and GP2 proteins generated
Figure 2 Light microscopy analysis of HEK-293T/17 cells
transfected with LASV gene constructs. Representative fields of
untransfected or vector control transfected (A), LASV NP or GPC (B),
or Z, Z+GPC, Z+NP, Z+GPC+NP (C) transfected HEK-293T/17 cells at
72 hours photographed in 6-well plates at 400X magnification are
shown. Control or single gene transfected cells retain fibroblastic
shape in undisturbed monolayers (A and B). By contrast, any
combination of LASV gene constructs that include the Z matrix
protein result in loss of fibroblastic cell shape, with pronounced
rounding and detachment from the Poly-D-Lysine coated plastic
surface, resulting in significant disturbance in the monolayer (C).
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Page 4 of 19in E. coli (Figure 3B, lane 10). Lectin binding to glycosy-
lated proteins included in the DIG Glycan Differentiation
Kit was included as a positive control (Figure 3B, lane 11).
A similar lectin binding analysis was obtained with VLP
purified through 20% sucrose cushions containing Z alone,
Z + G P C + N P ,Z + G P C ,o rZ + N P( F i g u r e3 C ,l a n e s1 -4 ,
respectively), with the exception that additional diffuse
bands could be discerned in VLP containing LASV glyco-
proteins (Figure 3C, lanes 2, 3).
LASV VLP glycoproteins display heterogeneous
glycosylation
LASV VLP containing Z+GPC+NP were treated with
PNGase-F, Endo-H, or neuraminidase to assess gross
glycosylation patterns. Experiments were performed with
non-denatured (Figure 4) and with heat denatured VLP
(data not shown), with identical results. PNGase-F
completely removed glycans from GP1 and GP2, as well
as from unprocessed GPC, as determined by mobility
shifts from 42 to 20 kDa for GP1, 38 to 22 kDa for GP2,
and from 75 to 42 kDa for GPC (Figure 4A,B, lane 2). By
contrast, Endo-H removed glycans from GP1, but to a
much lesser extent than from GP2. Multiple bands were
detected with a-GP1 mAb in Endo-H treated LASV VLP
containing GPC, ranging between 22 and 42 kDa,
whereas probing of the same reactions with a-GP2 mAbs
revealed a relatively homogeneous GP2 species at
approximately 30 kDa (Figure 4A,B, lane 3). Treatment
of LASV VLP with neuraminidase resulted in GP1 and
GP2 glycosylation patterns similar to those obtained with
untreated VLP (Figure 4A,B, lane 4 versus lane 1). Treat-
ment of LASV VLP with all three deglycosydases did not
affect the mobility of NP (Figure 4C, lanes 1 - 4) and Z
proteins (Figure 4D, lanes 1 - 4). In addition to deglyco-
sylation of monomeric glycoproteins and unprocessed
GPC, mobility shifts were readily detected for the
approximately 120 kDa species likely composed of pre-
viously characterized trimerized glycoproteins monomers
resistant to denaturation with SDS, reducing agents, and
heat (Figure 4A,B, lanes 3, 4) [11,12].
LASV VLP do not package cellular ribosomes
Ribonucleic acid content in LASV VLP generated in
HEK-293T/17 cells lacked 18S and 28S ribosomal RNA
(rRNA) species, as assessed by denaturing agarose gel
electrophoresis, irrespective of the LASV gene combina-
t i o n( F i g u r e5 A ,l a n e s2 ,4 ,6 ,8 ,1 0 ) .Al o wm o l e c u l a r
weight RNA species, approximately 75 base pairs or less,
corresponding in size range to cellular tRNAs could be
readily detected in VLP preparations containing either Z
alone, or in combination with NP and GPC (Figure 5A,
lanes 2, 4, 6, 8, 10). This species was not detected in
mock or pcDNA3.1+:intA transfected cell supernatants
extracted with Trizol reagent (data not shown). The 28S
Figure 3 Lectin binding profiles on sucrose purified VLP. LASV
Z+GPC+NP VLP fractions obtained from sucrose gradient
sedimentation corresponding to those in Figure 1A were subjected
to SDS-PAGE (3A) and lectin binding analysis on proteins transferred
to nitrocellulose membranes (3B). A combination of agglutinins,
GNA (Galanthus nivalis), SNA (Sambucus nigra), MAA (Maackia
amurensis), PNA (Peanut), and DSA (Datura stramonium), were
combined and used to probe VLP fractions 1 through 9 (3B, lanes
1 - 9). LASV NP, GP1, and GP2 generated in E. coli were used as
unglycosylated protein controls (3B, lane 10). A combination of four
glycoproteins was used as positive controls for lectin binding:
carboxypeptidase Y (63 kDa), transferrin (80 kDa), fetuin (68, 65, 61
kDa), and asialofetuin (61, 55, 48 kDa) (3B, lane 11). For visual
comparison purposes an SDS-PAGE gel was run with the same VLP
fractions, stained with Coomassie BB-R250, and photographed (3A,
lanes 1 - 9). LASV Z, Z+GPC+NP, Z+GPC, Z+NP VLP purified through
20% sucrose cushions were similarly analyzed for glycan binding
(3C, lanes 1 - 4, respectively). The relative positions of GPC, GP1, and
GP2 are noted to the left of the gel. Protein molecular weights in
kDa are noted to the right of each image.
Branco et al. Virology Journal 2010, 7:279
http://www.virologyj.com/content/7/1/279
Page 5 of 19and 18S ribosomal RNA bands were present in total cel-
lular fractions obtained from cells transfected with vary-
ing LASV gene constructs, although 28S/18S ratios were
significantly reduced when compared to the pcDNA3.1
+:intA transfected cell control (Figure 5, lanes 1, 3, 5, 7,
9, versus lane 11). To verify that input LASV VLP used
in RNA analysis contained the respective viral proteins,
aliquots of purified pseudoparticles were subjected to
western blots analysis with a-NP, a-HIS (Z), and a-GP2
antibodies. Western blot analysis revealed that input
LASV VLP expressed the respective proteins of interest
(Figure 5B, lanes 2, 4, 6, 8, 10).
LASV VLP are morphologically similar to native virions
Electron microscopy (EM) was employed to dissect the
morphological properties of VLP generated by expression
Figure 4 Deglycosylation analysis of LASV Z+GPC+NP VLP.
Non-denatured LASV Z+GPC+NP VLP were subjected to
deglycosylation with PNGase F (4A - D, lane 2), Endo H (4A - D, lane
3), neuraminidase (4A - D, lane 4), or were left untreated (4A - D,
lane 1), followed by SDS-PAGE and western blot analyses. Blots
were probed with a-GP1 (4A), a-GP2 (4B), a-6X-HIS (Z) (4D) mAbs,
or a-NP PAb (4C). PNGase F completely deglycosylated both GP1
and GP2 (4A, 4B, lane 2, respectively), resulting in a mobility shift of
both proteins corresponding to their unprocessed polypeptide
backbone molecular weights, of 20 kDa and 23 kDa, respectively.
Conversely, Endo H showed little affect of GP1 (4A, lane 3) but
significantly deglycosylated GP2, generating a relatively uniform,
partially glycosylated species of ~ 30 kDa (4B, lane 3). Following
Endo H digestion, which cleaves high mannose and some hybrid
oligosaccharides from the backbone of N-linked glycoproteins, ~ 7
kDa of the GP2 mass remains inaccessible to this enzyme. Similar
results were obtained when pre-denatured VLP were used as input
in the reaction. Neuraminidase had no affect on the glycosylation
profile of GP1, GP2, or GPC (4A, 4B, lane 4). None of the
deglycosidases affected the mobility of NP (4C, lanes 2 - 4) or Z (4D,
lanes 2 - 4) proteins. Protein molecular weights in kDa are noted to
the right of each blot.
Figure 5 Analysis of RNA content in LASV VLP and
corresponding transfected HEK-293T/17 cells. RNA was isolated
from the total VLP fraction generated in a single 10 cm cell culture
dish (~ 6 ×10
7 cells), and the entire nucleic acid pellet was resolved
on denaturing glyoxal agarose gels. RNA from Z3’HIS, Z3’HIS+GPC,
Z3’HIS+NP, Z3’HIS+GPC+NP, and Z+GPC+NP (lanes 2, 4, 6, 8, and 10,
respectively [V]), and 5 μg of total RNA isolated from the
corresponding transfected HEK-293T/17 cells (lanes 1, 3, 5, 7, and 9,
respectively [C]) were resolved per lane of a 1.5% gel. Untransfected
HEK-293T/17 cell RNA was run alongside test samples as a control
(lane 11 [C]). All VLP samples were devoid of rRNAs (28S ~5.5 kbp;
18S ~ 1.8 kbp), but all contained low molecular weight RNA species
corresponding in size to tRNAs, approximately 50 - 100 nucleotides
in length (lanes 2, 4, 6, 8, 10). Transfected cells producing LASV VLP
showed a significant reduction in the 28S rRNA species (lanes 1, 3,
5, 7, 9) when compared to untransfected control cells (lane 11).
Ratios of 18S/28S RNA in transfected and untransfected cells,
determined by densitometry, are shown below panel A. Molecular
weight sizes ranging from 0.5 - 6 kbp are noted to the left of the
gel. The positions of cellular 28S and 18S ribosomal RNAs, and tRNA
are noted to the right of the gel.
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Page 6 of 19of Z matrix protein alone, or in combination with NP and
GPC. Expression of LASV Z gene alone was sufficient to
induce budding of low electron density empty VLP from
the surface of transfected cells (Figure 6A). By contrast,
expression of Z in conjunction with NP or NP+GPC
resulted in the generation of electron dense VLP with
granular material associated with the pseudoparticles
(Figure 6B,C,D). The granular structures were similar in
size to cellular ribosomes, or ~ 20 nm (Figure 6D), but
identification of these subcellular organelles as the granu-
lar elements, as well as their physical association and
incorporation in VLP were not investigated in these stu-
dies. LASV VLP displayed pleiomorphic morphology by
EM, with sizes ranging from 100 - 250 nm, and envel-
oped by a bilayer structure (Figure 6D).
LASV VLP display glycoprotein resistance to proteolysis
by trypsin
Trypsin protection assays were employed to characterize
protein content and structural compartmentalization of
LASV antigens. Treatment of VLP with soybean trypsin
inhibitor alone, with 1% Triton X-100 alone, or with
soybean trypsin inhibitor and trypsin had no effect on
the integrity of GP1, GP2, Z, and NP proteins when
compared to untreated controls (Figure 7A - 7D, lanes
2, 3, 6 versus lane 1). Treatment of VLP with trypsin
alone completely digested the approximately 120 kDa
trimerized GP1 species and partially digested unpro-
cessed GPC, while monomeric GP1 remained largely
resistant to the protease (Figure 7A, lane 4). Similarly,
trypsin completely digested the approximately 120 kDa
trimerized GP2 species, but only partially digested
monomeric GP2 (Figure 7B, lane 4). Trypsin treatment
of intact LASV VLP did not significantly affect detection
of NP and Z proteins (Figure 7C,D, lane 4). Whereas,
treatment of LASV VLP with Triton X-100 and trypsin
resulted in increased digestion of both glycoproteins,
but significant levels of GP1 and GP2 could still be
detected (Figure 7A,B, lane 5). Under these conditions,
both NP and Z proteins were completely digested by
trypsin (Figure 7C,D, lane 5). Digestion of intact VLP in
t h ep r e s e n c eo fs o y b e a nt r y p sin inhibitor completely
prevented digestion of any form of the exposed glyco-
protein complex (Figure 7A,B, lane 6).
LASV VLP are immunogenic in mice and induce a mature
IgG response after prime + two boosts intra-peritoneal
immunizations
Mice were immunized with LASV VLP containing Z
and the glycoprotein complex (Z+GPC), or including
the NP protein (Z+GPC+NP), in the absence of an adju-
vant, using a prime + 2 boosts schedule, 3 weeks apart.
Total LASV antigen-specific IgG levels were assessed by
ELISA on VLP, NP, GP1, or GP2 coated plates. Three
Figure 6 Electron micrographs of LASV VLP budding from the
surface of HEK-293T/17 cells expressing LASV Z alone or in
combination with GPC and NP genes, and high magnification
of LASV pseudoparticles. Cells expressing LASV Z (6A), Z+NP (6B),
or Z+NP+GPC (6C) were harvested at 72 hours post transfection,
fixed in glutaraldehyde, and embedded in agarose plugs. Cell
pellets were processed for EM analysis and were imaged. Images
were printed on photographic paper and were subsequently
scanned and saved as high resolution tiff files. LASV Z VLP budded
from the surface of cells as empty particles, noted by the lack of
electron dense cores (6A). By contrast, LASV Z+NP and Z+NP+GPC
appear as electron dense particles containing subcellular structures
(6A and 6B). LASV VLP budding from the surface of transfected cells
or approaching the cell surface are marked by black arrows. Budded
LASV Z+NP+GPC VLP appeared as round, dense structures
enveloped in a bilayer structure, presumably a lipid envelope, and
were associated with electron dense subcellular organelles (6D).
These organelles were not identified as ribosomes in these studies.
Cellular ribosomes are known to associate with and be packaged
into native LASV virions. The bar in each Figure equals 100 nm.
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VLP a significant number of mice had generated IgG-
specific responses to LASV antigens (Table 1, pre-1
st
boost column). Following a homologous first boost, all
animals generated more robust LASV protein-specific
IgG, which was further enhanced in all animals after a
second boost, and assessed terminally 63 days post first
immunization (Figure 8; Table 1). The IgG response
against both types of whole VLP was significantly more
robust than to individual antigens, with mean endpoint
titers of 12,800 and 32,000 for Z+GPC and Z+GPC+NP
VLP, respectively. Most notably terminal IgG titers
against GP1 and GP2 in Z+GPC+NP VLP were approxi-
mately 15 fold higher than to Z+GPV VLP. Most ani-
mals immunized with Z+GPC VLP responded poorly to
both glycoproteins, with 2/10 and 3/10 producing end-
point titers of 50 to GP2 and GP1, respectively, with
only one animal registering an IgG titer of 3200 to GP2.
Animals immunized with Z+GPC+NP responded well to
both glycoproteins, with mean titers of 10,400 and 6,800
for GP2 and GP1, respectively, with 4/10 animals regis-
tering greater than 12,800 endpoint titer to each glyco-
protein. Despite an increased response to GP2 in
animals immunized with Z+GPC+NP statistical signifi-
cance was not achieved versus the GP2 response to Z
+GPC VLP (Table 1). Titers to Z matrix protein were
not determined in these studies.
LASV patient sera specifically recognize VLP antigens in
conformational and individual recombinant viral proteins
LASV-specific IgM and IgG titers in convalescent sub-
jects and patient sera were used to characterize humoral
responses to quasi-native viral epitopes on VLP. A sub-
set of sera reacted with LASV VLP in either IgM or IgG
detection platforms, but usually not both (Figure 9A,C).
None of the presumed negative control samples showed
reactivity to LASV VLP in these assays (Figure 9A,B,
lanes BOM002, BOM011, BOM020). The positive
Figure 7 Trypsin protection assay on LASV Z+GPC+NP VLP.
LASV VLP expressing Z, GPC, and NP proteins were subjected to
trypsin protection assays to assess the enveloped nature of
pseudoparticles and compartmentalization of viral proteins. LASV
VLP incorporated unprocessed 75 kDa GPC precursor (7A, 7B, lane
1), and monomeric 42 kDa GP1 (7A, lane 1), and 38 kDa GP2 (7B,
lane 1). LASV VLP also incorporated trimerized, non-reduceable 126
kDa GP1 isoforms (7A, lane 1), and 114 kDa GP2 trimers to a lesser
extent (7B, lane 1). For trypsin protection assays ten μg of LASV VLP
were either left untreated (lane 1), treated with 3 mg/mL soybean
trypsin inhibitor (lane 2), 1% Triton X-100 (lane 3), 100 μg/mL trypsin
(lane 4), 1% Triton X-100 and 100 μg/mL trypsin (lane 5), or 100 μg/
mL trypsin in the presence of 3 mg/mL soybean trypsin inhibitor
(lane 6). Trypsin alone completely digested trimerized GP1 (7A, lane
4) and GP2 (7B, lane 4), while partially degrading GPC precursor, but
having little effect on monomeric glycoproteins. Trypsin treatment
of intact VLP did not significantly affect the levels of NP (7C, lane 4),
and Z (7D, lane 4) proteins. Treatment of VLP with Triton X-100 in
the presence of trypsin resulted in the complete digestion of NP
(7C, lane 5) and Z (7D, lane 5), while only partially degrading
monomeric GP1 (7A, lane 5) and GP2 (7B, lane 5) proteins.
Treatment of VLP with trypsin in the presence of soybean trypsin
inhibitor completely prevented digestion of any form of all viral
proteins (7A - 7D, lane 6).
Table 1 Increasing IgG titers to Lassa virus antigens through the vaccination schedule
Immunogen
Z+GPC VLP Z+GPC+NP VLP
ELISA Ag naive pre- 1
st
boost
pre- 2
nd boost term. naive pre- 1
st
boost
pre-
2
nd boost
term. p value
VLP 18 ±
17
556 ±
975
2667 ±
1058
12800 ±
14311
50 ±
0
9920 ±
4637
19520 ±
16963
32000 ±
20239
0.026
sGP1 <10 88 ±
69
200 ±
254
444 ±
384 **
<10 1520 ±
1159
2480 ±
1159
6800 ±
5215
0.004
GPCΔTM <10 95 ±
72
215 ±
217
700 ±
992 *
<10 2960 ±
3657
3440 ±
3478
10400 ±
15179
0.092
NP <10 560 ±
310
1220 ±
1060
2000 ±
1265
Endpoint ELISA titers for each timed point are mean ± SD, N = 10, except for starred entries, where * N = 9 and ** N = 8. The p value for terminal endpoint IgG
titers generated against relevant LASV antigens between the two VLP formats is shown. Samples were collected on days 21 (pre-1
st boost), 42 (pre-2
nd boost)
and 63 (term.) for titer analysis.
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Page 8 of 19Figure 8 Immunogenicity of LASV Z+GPC and Z+GPC+NP in a prime + 2 boosts regimen in BALB/c mice.G r o u p so f1 0B A L B / cm i c e
were immunized i.p. with either 100 μL of sterile TNE, or 10 μg of LASV VLP formulated in the same buffer using a prime + 2 boosts regimen,
3 weeks apart. Three weeks after the second boost all mice were sacrificed and sera were subjected to murine IgG endpoint titer determinations
by ELISA on homologous VLP or recombinant LASV proteins coated on Nunc Maxisorp plates. Endpoint titers were calculated using background
subtraction binding values generated with normal mouse sera on recombinant VLP and LASV proteins. LASV Z+GPC immunizations generated
significant titers against whole VLP (mean = 12,800), but generally low titers to viral GP1 and GP2, with means of 444 and 700, respectively (8A).
A similar immunization schedule with LASV Z+GPC+NP VLP resulted in significantly higher endpoint titers to both glycoproteins, with means of
6,800 and 10,400 for GP1 and GP2, respectively (8B), and to whole VLP (mean = 32,000). Significant IgG titers were also generated to NP (mean
= 2,000). Endpoint titers generated by sham immunized murine sera to recombinant LASV proteins were at the lower limit of detection of the
assay (mean = 10), with slight increased non-specific titers against Z+GPC VLP (mean = 18) and Z+GPC+NP (mean = 50). The immunization
schedule used in these experiments is graphically outlined in 7C.
Branco et al. Virology Journal 2010, 7:279
http://www.virologyj.com/content/7/1/279
Page 9 of 19Figure 9 Binding profile of human serum IgM and IgG, and NP-specific mAbs on LASV VLP and recombinant nucleoprotein.H u m a n
sera collected from household contacts of patient G676, individuals hospitalized at the KGH at the time of analysis, or from supposedly LASV
naive controls were diluted 1:100 in a proprietary sample diluent buffer containing 0.05% Tween 20 (Corgenix Medical Corp.) and assayed by
ELISA on plates coated with 2 μg/mL total VLP protein (Figure 9A, 9C) or 2 μg/mL rNP (Figure 9B, 9D) per well. Detection of bound human IgM
(Figure 9A, 9B) or IgG (Figure 9C, 9D) was performed as outlined in methods. LASV VLP captured IgM from three samples (G676-M, G676-Q,
G688-1), all of which were also detected by rNP ELISA (Figure 9A, 9B), but did not result in binding by IgM from 14 additional samples that also
tested positive on rNP (Figure 9A, 9B), including the G652-3 positive control. Similarly, VLP detected LASV-specific IgG in 2 samples (G679-2,
G679-3), but did not identify 24 others detected in rNP ELISA (Figure 9C, 9D). For analysis of mAb binding profiles LASV VLP were coated in high
protein binding ELISA plates at the same concentration as above. The indicated NP-specific mAbs were then used in a binding assay, at 1 μg/
mL, alongside mouse IgG as a negative control (Figure 9E). For capture and detection of NP in solution, each NP-specific mAb was coated on
ELISA plates at 5 μg/mL, followed by incubation with serial dilutions of nucleoprotein in sample diluent (Figure 9F). Captured NP was detected
with a polyclonal Goat a-NP-HRP conjugate.
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sent format (Figure 9A,C, lane G652-3(PC)), although it
bound to rNP in both IgM and IgG assays format
(Figure 9B,D, lane G652-3(PC). Overall, there was poor
correlation between LASV VLP and rNP detection of
viral protein-specific IgG and IgM in human sera. Char-
acterization of LASV NP epitope presentation in the
context of a VLP was performed by ELISA using a series
of mAbs raised against recombinantly expressed LASV
NP. All five NP-specific mAbs showed differential bind-
ing levels to NP in VLP (Figure 9E), despite all captur-
ing recombinantly expressed NP in solution at the
concentration tested (Figure 9F).
Discussion
Lassa virus-like particles were generated to contain the
major immunological determinants of the virus,
resembled native virions structurally, and were immuno-
genic in mice. Plasmid vectors well suited for high level
expression of recombinant proteins in mammalian cells
through combination of rational design and proven
g e n e t i ce l e m e n t sh a v er e s u l t e di nh i g hy i e l d so fL A S V
VLP. These vectors afford the possibility of developing a
VLP-based vaccine candidate in mammalian cell systems
at low cost per dose, using transient expression technol-
ogies. Despite incorporation of all LASV proteins into
VLP, both glycoproteins were present at significantly
higher levels in most sucrose density fractions than
either NP or Z (Figure 1). Incorporation of high levels
of both glycoproteins in VLP may be beneficial in a vac-
cine platform, as these viral components alone have
been shown to confer full protection against challenge
with lethal doses of live LASV in non-human primates
[17-21]. Yet, despite the high levels of glycoprotein
incorporation into LASV VLP, addition of the nucleo-
protein may be of critical importance in establishing
more robust and long lived immunity against Lassa
virus [19,22]. Previous studies have demonstrated physi-
cal interaction between the glycoprotein complex, the Z
matrix, and nucleoproteins during viral biogenesis
[23-25]. Thus, these natural interactions are greatly ben-
eficial since they result in the generation of VLP that
package all viral immunogenic and protective determi-
nants from a single set of transiently transfected recom-
binant LASV genes. In these studies we employed the
human endothelial kidney cell line HEK-293T/17 for its
high levels of transfectability, expression of recombinant
proteins from human cytomegalovirus (hCMV) promo-
ter driven gene constructs, and resulting yields of LASV
VLP. During the course of this work, we have also
established the value of using HEK-293T/17 as an indi-
cator cell line. The profound morphological changes
manifested by the cell line upon expression of LASV Z
matrix protein is a good indicator of transfection
efficiency and overall production levels of resulting VLP
(Figure 2). Despite significant adverse metabolic effects
on cells expressing LASV proteins and generating bud-
ding VLP, culture viability remained high (mean = 70%)
at the time of harvest. This desirable aspect of mamma-
lian cell culture-based production is beneficial in down-
stream purification processes, by reducing host cell
components that must be eliminated from the final pur-
ified product, namely the cellular proteins, DNA, RNA,
and lipids. Other expression platforms cannot be easily
employed in the generation of LASV VLP where the gly-
coprotein complex precursor is used to incorporate pro-
cessed GP1 and GP2. Truncated versions of the GPC
precursor lacking the transmembrane domain have been
generated in E. coli (unpublished data from the Viral
Hemorrhagic Fever Research Consortium) and in bacu-
lovirus expression systems [26]. In E. coli, the protein is
neither glycosylated nor cleaved into GP1 and GP2 sub-
units. In insect cells, the protein is glycosylated but is
not cleaved [26]. Both expression systems lack the criti-
cal SKI-1/S1P subtilase responsible for co-translational
processing of the LASV GPC precursor in mammalian
cells [27]. Despite the possibility of co-expressing the
subtilase in heterologous systems to facilitate processing
of GPC precursor, the glycosylation profile of GP1 and
GP2 subunits may play a critical role in the structure
and function of each protein in vivo. Thus, a mamma-
lian expression system remains a highly attractive plat-
form for the development of an arenaviral VLP-based
vaccine.
We have determined in these studies that LASV VLP
contain, in addition to the intended viral polypeptides, a
plethora of host cell membrane proteins, presumably
acquired during budding from the cell membrane or
other intracellular lipid bilayer containing structures,
such as the Golgi apparatus. A significant portion of the
viral envelope protein content is made up of host cell
glycoproteins, as determined by a broad glycan binding
analysis performed on sucrose sedimented fractions
(Figure 3B,C). The host cell glycoprotein composition
varies along the gradient spectrum (Figure 3B). A similar
pattern of cellular glycoproteins incorporated into LASV
VLP was detected in purified particles generated from
expression of Z alone or in combination with GPC and
NP (Figure 3C). In Z+GPC or Z+GPC+NP VLP, a dif-
fuse lectin binding pattern could be detected between
38 and 42 kDa which was absent from VLP that did not
express the glycoprotein complex. This pattern was
detected in addition to a prominent ~ 48 kDa cellular
glycoprotein of unknown identity present in all VLP for-
mats (Figure 3 C). The majority of detected cellular gly-
coproteins incorporated into LASV VLP ranged from 30
to greater than 220 kDa in mass. Recently, Moerdyk-
Schauwecker et al. 2009 [28] characterized the spectrum
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cular stomatitis virus (VSV), an enveloped virus, during
viral biogenesis. In total, 64 proteins of host cell origin
were identified via a proteomics approach coupled with
mass spectrometry (MS). Of the 64 host cell proteins
identified in these studies, 10 were glycoproteins [28].
Although a similar study has not been performed for
any member of the arenaviridae, it is likely that some
common host cell proteins are packaged among a wide
array of viral classes, and some of these proteins may
even play functional roles during viral infection and
replication. Characterization of the host cell protein pro-
file in LASV VLP will be paramount in gaining regula-
tory clearance of an arenaviral pseudoparticle-based
vaccine. The immunological and functional role of such
proteins must be known in order to avert untoward side
effects, such as autoimmunity and physiological
disregulations.
We had previously characterized the gross glycosyla-
tion profile of LASV GP1 in the context of a soluble iso-
form (sGP1) of this viral protein [12]. In the present
studies, we characterized LASV VLP-associated GP1 and
GP2 glycosylation patterns. Glycoprotein 1 associated
with VLP generated essentially the same glycosylation
pattern as sGP1, with only partial deglycosylation by
Endo H, and insignificant processing by neuraminidase
(Figure 4A). These results point to a heterogeneous
array of glycans on the surface of GP1 that include
some high mannose and branched oligosaccharides. Gly-
coprotein 2 displayed a more heterogeneous glycan
array with a highly homogeneous high mannose and
hybrid oligosaccharide content that accounted for
approximately 8 kDa of the fully processed mass of the
protein, based on the detection of a relatively sharp 30
kDa species upon treatment with Endo H (Figure 4B,
lane 3). The remaining 7 kDa of glycan content could
be removed by treatment of the protein with PNGase F,
but not with neuraminidase (Figure 4B, lanes 2 and 4).
A similar micro- and macroheterogeneity in both GP1
and GP2 N-linked glycosylation has not been character-
ized in native Lassa virions.
Through these studies, we have established that GP1
incorporated into LASV VLP is highly resistant to pro-
teolytic digestion by trypsin (Figure 7A, lanes 4 and 5),
despite 13 predicted trypsin recognition sites on the
polypeptide backbone (ExPASy proteomics server tools,
PeptideCutter [29]). Similarly, GP2 is resistant to diges-
tion with trypsin, albeit to a lesser extent than GP1,
even after solubilization of the pseudoparticle envelope
with Triton X-100 (Figure 7B, lanes 4 and 5). The Pepti-
deCutter tool in ExPASy predicted 25 recognition sites
with high confidence in the GP2 polypeptide backbone.
However, since the glycoprotein complex spike is the
viral antigen most readily accessible to the innate
immune system and to circulating serum proteases, it is
likely that this molecule evolutionarily developed a sig-
nificant level of proteolytic resistance in the structure-
function relationship. It is of paramount importance to
the virus that the critical components required for bind-
ing and fusion to permissive host cells be preserved.
The specific glycosylation patterns on GP1 and GP2
may play a functional role in the observed resistance to
proteolytic degradation. In the studies by Schlie et al.
2010 [23], Proteinase K protection assays performed on
GP VLP also revealed partial resistance of the GP2 com-
ponent against degradation by the protease, although
solubilization with Triton X-100 in conjunction with
protease resulted in complete digestion of the protein.
Glycosylation of arenaviral glycoproteins is critical for
protein stability, as unglycosylated GP1 and GP2 gener-
ated in E. coli are insoluble and require detergents, zwit-
terions, and reducing agents to remain in solution
[11,30], and deglycosylating mammalian cell generated
GP1 generally produces similar results (unpublished
data).
To characterize the structural compartmentalization of
viral proteins in LASV we performed trypsin protection
assays in the absence or presence of the anionic deter-
gent Triton X-100 (Figure 7). In the absence of deter-
gent, trypsin completely digested non-reduceable GP1
trimer, partially degraded unprocessed GPC, but had no
effect of monomeric GP1 (Figure 7A, lane 4). A similar
digestion pattern was obtained for GP2 (Figure 7B, lane
4). The addition of detergent to the reaction enhanced
digestion of unprocessed GPC and had a minor effect
on sensitivity of GP1 to the protease (Figure 7A, lane 5).
Dissolution of the envelope by detergent resulted in
more pronounced degradation of GP2 by trypsin,
although a significant portion of the monomer could be
detected (Figure 7B, lane 5). Only treatment of LASV
VLP with Triton X-100 resulted in proteolytic degrada-
tion of both Z matrix and NP proteins. These results
strongly support the model of a LASV VLP containing
glycoprotein spikes on the surface of a lipid envelope
with an internal matrix of Z protein containing the
nucleoprotein component. We have shown that the viral
proteins NP, Z, GP1 and GP2 can be co-expressed in
VLP. Protein-protein associations appear to be an
important aspect to the formation of VLP. Schlie et al.
2010 [23] reported that a co-localization of NP, Z, and
GP occurs near the nucleus. Similarly, Eichler et at.
2004 [24] demonstrated that NP and Z co-localize in
the cell. They also demonstrated that NP could be preci-
pitated using an antiserum against Z and vice versa.
Furthermore, Schlie et al. 2010 [23] determined that NP
did not influence the interaction of GP and Z, nor could
an interaction between NP and GP be detected in the
absence of Z in co-localization and immunoprecipitation
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formed by Schlie et al. 2010 [23] demonstrated an asso-
ciation between Z and GP and Z and NP. Strecker et al.
2006 [25] reported that Z myristoylation is important
for binding to lipid membranes. Flotation experiments
using wild-type Z protein and a mutant of Z at the myr-
istoylation site showed that the mutant remains loca-
lized in the cytosol, whereas the wild-type associated
with the membrane. Thus, the interactions between Z
and the membrane and with GP and NP result in VLP
formation with relevant proteins incorporated in virions.
Another structural component of native LASV virions
are host cell ribosomes that are packaged during virion
assembly, presumably for enhanced viral mRNA transla-
tion in the early stages of cellular infection. To deter-
mine whether LASV VLP containing any combination
of Z matrix, GPC, and NP proteins mediated the ability
to package cellular ribosomes, total RNA was isolated
from pseudoparticles and analyzed by denaturing RNA
gel electrophoresis (Figure 5). RNA was also isolated
from the corresponding transfected cells and analyzed
alongside VLP RNA. All VLP formats analyzed in these
studies did not contain significant levels of the 28S and
18S ribosomal RNA species known to be critical compo-
nents of mammalian ribosomes (Figure 5, lanes 2, 4, 6,
8, 10). In some analyses, RNA was purified from 1 mg
of total purified VLP, and the entire purified nucleic
acid fraction was analyzed by gel electrophoresis without
distinct ribosomal RNA bands visible (data not shown).
Despite the lack of rRNA detection in LASV VLP, all
pseudoparticle formats analyzed in these studies con-
tained significant levels of low molecular weight RNA
species ~ 75 - 200 nt, that co-migrated with cellular 5S
(120 nt) and 5.8S (160 nt) rRNA, and transfer RNAs
(75 - 95 nt). It is reasonable to assume that in native
VLP the incorporation of host cell ribosomes would
result in the co-packaging of critical tRNAs for transla-
tion of viral mRNAs. Although in these studies the
exact nature of the packaged RNA species was not char-
acterized in detail, the results suggest that multiple RNA
species of ribosomal origin are incorporated into VLP.
To confirm that ribonucleoproteins were not incorpo-
rated into virions, we performed western blot analysis
on VLP proteins using antibodies raised against U1
snRNP 70, La/SSB, and Ro/SSA. No ribonucleoproteins
could be detected in pseudoparticles (data not shown).
These studies also point to a critical presence of viral
RNA polymerase and genomic RNA segments during
replication for subsequent incorporation of host cell
ribosomes into nascent viral particles. The lack of
detectable ribosomes in LASV VLP represents a regula-
tory advantage for this platform as a vaccine candidate.
Administration of pseudoparticles containing autologous
ribosomes to vaccinees has potential to result in unto-
ward immunological affects.
Despite the lack of detectable 28S and 18S rRNA in
LASV VLP comprised of any combination of LASV
proteins analyzed in these studies, pseudoparticles that
contained GPC and/or NP in addition to Z matrix
protein were morphologically similar to native virions
(Figure 6B,C,D). These VLP were electron dense parti-
cles with punctuate inclusions and appeared to associate
with highly electron dense subcellular organelles in the
cytoplasm, possibly ribosomes despite their lack of
incorporation into the pseudoparticle (Figure 6C,D).
The size of mammalian ribosomes is approximately 20
nm, in line with the size of the particles associated with
nascent LASV VLP imaged in these studies (Figure 6D).
However, these subcellular structures could not be
detected in VLP budding from the surface of cells trans-
fected with Z matrix protein alone (Figure 6A), which
appeared empty and containing only an envelope struc-
ture, as shown here and reported by others [31].
For immunizations, LASV VLP comprised of Z+GPC
or Z+GPC+NP were formulated in PBS and used to
immunize BALB/c mice, in a prime + 2 boosts schedule,
3 weeks apart, in the absence of an adjuvant, and admi-
nistered by i.p. injection. After a single immunization
some animals showed a low level IgG response to indivi-
dual LASV antigens, with increasing mean antibody
titers after each subsequent boost (Table 1). ELISA
analysis of terminal IgG titers showed a clear difference
in the response levels against GP1, and whole VLP
between Z+GPC and Z+GPC+NP pseudoparticles (p =
0.004 and 0.026, respectively) (Figure 8A,B). VLP con-
taining all three proteins induced a significantly higher
response to the glycoprotein components compared to
Z+GPC VLP, with a 15 fold overall increase in titer
against both GP1 and GP2, despite a not quite signifi-
cant statistical difference in the GP2 titers (p = 0.092).
Likewise, the titers against whole Z+GPC+NP VLP were
nearly 3 fold higher than to Z+GPC pseudoparticles
(Figure 8A,B).
Lastly, we attempted to use LASV VLP as a diagnostic
tool for the detection of viral protein-specific IgM and
IgG in the serum of convalescent subjects, patients from
the Lassa ward, contacts from patients who succumbed
to Lassa fever, and individuals not known to have had
the febrile illness at any given time in their lives. The
LASV antigen binding profile of these sera was exten-
sively characterized using highly sensitive and specific
recombinant protein-based diagnostics under develop-
ment by the Viral Hemorrhagic Fever Research Consor-
tium. The overall poor level of correlation observed in
human serum IgM (r = 0.3297; r
2 = 0.1087) and IgG
(r = 0.6284; r
2 = 0.3949) binding profiles between LASV
Branco et al. Virology Journal 2010, 7:279
http://www.virologyj.com/content/7/1/279
Page 13 of 19VLP and recombinant proteins in these studies was not
surprising. Recombinant LASV proteins currently
employed in diagnostic assays are generated in bacterial
or mammalian cell systems, as outlined in Branco et al.,
2008 [12], and Illick et al., 2008 [11]. Individually pro-
duced, purified, and characterized proteins are used
alone or in combination to coat high protein binding
ELISA plates for determination of serum IgM and IgG
binding profiles. Thus, it would be expected that pro-
tein-protein interactions known to play a role during
viral biogenesis and in the formation of LASV VLP
result in presentation of different epitopes and confor-
mations than in counterparts generated as individual
polypeptides. The known interactions between Z, GPC,
a n dN Pp r o t e i n si naV L Pf o r m a tl i k e l ym a s kt h ep r e -
sentation of relevant epitopes to which a given indivi-
dual may have generated IgM and IgG. As a result,
native presentation of antigens in the context of a VLP,
e v e ni nt h ep r e s e n c eo fl o wl e v e l so ft h em e m b r a n e
solubilizing detergent Tween 20, will likely not result in
disruption of protein interactions necessary for the
detection of epitope-specific serum antibodies. This is
supported by the fact that all five NP-specific mAbs
used in this analysis detected and captured recombi-
nantly expressed NP in solution (Figure 9F), albeit at
different levels. In combination, these results strongly
suggest that LASV proteins in the context of a VLP dis-
play epitopes that possibly mimic native conformation
and presentation. These observations further support
the use of LASV VLP as a vaccine platform by supplying
aq u a s i - n a t i v ea n t i g e n ,t h u sa l l o w i n gt h ei n n a t ea n d
adaptive immune systems to preferentially target epi-
topes relevant for immune protection against the virus.
In addition, the use of pseudoparticles in clinical assays
may offer advantages over the use of recombinantly
expressed individual proteins. Immune responses to
LASV VLP may be directed against epitopes that are
best or exclusively displayed in the context of a quasi
native particle containing proteins assembled in a man-
ner similar to functional viral biogenesis.
VLP have gained significant momentum in the past
decade as premier vaccine platforms. The approval of
Merck & Co., Inc.’sG a r d a s i l
(r) (Human Papillomavirus
Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recom-
binant) by regulatory agencies heralded a new era in
vaccinology, demonstrating that VLP are immunogenic,
safe, and well tolerated in humans, and confer nearly
complete protective immunity against homologous viral
strains in canine models [32-38]. ENGERIX-B [Hepatitis
B Vaccine (Recombinant)] is a recombinant VLP-like
hepatitis B vaccine developed and manufactured by
GlaxoSmithKline plc. These “Dane” particles, generated
in yeast strains, are comprised of HbsAg and yeast phos-
pholipids, and are subsequently harvested by gradient
centrifugation and properly disulfide-linked in vitro [39].
These particles are highly immunogenic, safe, well toler-
ated, and very efficacious.
VLP-based vaccine candidates have also been devel-
oped and tested for their efficacy in preventing a wide
array of viral conditions, such as Influenza [40-44], Ebola
[45,46], Marburg [45,47], West Nile virus [48], Dengue
[49], Respiratory Syncytial Virus (RSV) [50], HIV [51-56],
and Hepatitis C virus [57-59], and the most recently
reported case of Chikungunya [60]. VLP platforms cur-
rently being evaluated toward clinical licensure include
Novavax’s trivalent seasonal influenza vaccine. In recent
Phase II clinical trials the vaccine was well tolerated and
safe in adults age 60 and older and in healthy volunteers
18 to 48 years of age [61,62]. Thus, it is reasonable to
employ similar strategies to develop a vaccine platform
based on VLP that contain all the relevant immunological
determinants that are known to confer protective immu-
nity against this viral hemorrhagic fever. Studies are cur-
rently ongoing to determine the in vivo efficacy of LASV
VLP in relevant in vivo models.
Conclusions
The generation and characterization of a LASV VLP
platform displaying all major immunological and protec-
tive determinants of the virus, with quasi-native mor-
phological and protein association properties, that
induced significant IgG titers in mice potentiate further
development as a viable human vaccine platform.
Presently, there is no licensed vaccine or anti-viral
therapy available for the prevention or treatment of this
disease, and there is no commercially available Lassa
fever diagnostic assay. The threat posed by LASV is
heightened further by the potential use of the virus as a
biological weapon, which is substantiated by the stability
of the virion, demonstrated person-to-person transmis-
sion, the severity of disease, lack of therapeutic and pro-
phylactic reagents, and the capacity for aerosolization.
Collectively, these factors underscore the need for effec-
tive diagnostics, vaccines, and therapies against Lassa
fever. The work performed in these studies is a first step
toward resolving a public health crisis in Africa and bio-
terrorism concerns elsewhere.
Methods
Cells, plasmids, antibodies
HEK-293T/17 cells (ATCC CRL11268) were maintained
in complete high glucose Dulbecco’s Modified Eagle
Medium (cDMEM) supplemented with non-essential
amino acids (NEAA) and 10% heat-inactivated fetal
bovine serum (ΔFBS).
Plasmid constructs expressing LASV GPC and the
backbone vector pcDNA3.1+zeo:intA were described
elsewhere [11]. Optimized Z and NP genes for expression
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RNA, as previously outlined [11]. For immunoassays, Dr.
Randal J. Schoepp kindly provided the LASV-specific
GP1 mAb L52-74-7A and GP2 mAb L52-216-7, which
were generated against purified gamma-irradiated LASV,
as previously described [13]. Monoclonal antibody to
poly-histidine (6X-HIS) was purchased from Invitrogen,
Inc. LASV NP-specific polyclonal sera were generated in
goats by immunizing animals with 100 μgo fE.coli gener-
ated protein per injection, using a prime + 3 boosts strat-
egy, followed by terminal bleeds (Bethyl Laboratories,
Inc.). The LASV NP-specific goat IgG fraction was subse-
quently purified by affinity column chromatography with
agarose beads coupled to NP immobilized by AminoLink
chemistry (Thermo Fisher Scientific, Inc., Rockford, IL).
Horseradish peroxidase (HRP)-conjugated secondary
antibodies specific for goat and mouse IgG-gamma were
purchased from Kirkegaard and Perry Laboratories (KPL,
Gaithersburg, MD). The NP-specific hybridomas NP
33LN, NP 100LN, NP 61SP, NP 692SP, and NP 1474SP
were generated by fusion of the SP2/0-Ag14 myeloma
cell line with splenocytes and mesenteric lymph node
lymphocytes from BALB/c mice immunized with E. coli-
expressed NP, essentially as outlined by Köhler and Mil-
stein [63-65]. Monoclonal antibodies were produced in
serum free medium (PFHM II, Invitrogen), purified via
Protein-G chromatography, quantitated by A280, BCA,
and SDS-PAGE.
Transient expression of LASV gene constructs
Recombinant LASV protein expression was analyzed in
HEK-293T/17 cells transiently transfected with mamma-
lian expression vector DNAs, which were prepared
using the Endo-Free PureLink HiPure plasmid filter
maxiprep kit (Invitrogen, Carlsbad, CA). Transfections
and preparation of cell extracts for protein analysis have
been described elsewhere [11]. The negative control vec-
tor pcDNA3.1(+):intA was included in all transfections.
Protein concentration was determined for each sample
by A280 with A260 subtraction, and verified using a
Micro BCA(tm) Protein Assay Kit, as outlined by the
manufacturer (Thermo Scientific).
Generation and purification of LASV VLP
LASV VLP were generated by transfecting HEK-293T/17
cells in 6-well plates (for small scale analysis) or in 15 cm
plates (for purification of multi-milligram quantities of
VLP) using Lipofectamine 2000 (Invitrogen). Cells were
seeded on plates coated with 50 μg/mL Poly-D-Lysine
hydrobromide, and were transfected only at ≥90% conflu-
ence. Monolayers were transfected with equimolar
amounts of vector DNAs, and when required reactions
were normalized for DNA content with empty pcDNA3.1
(+):intA. Cell supernatants were harvested 4 days post
transfection and were clarified by centrifugation at
4000 ×g for 20 minutes at room temperature. Clarified
supernatants were transferred to Beckman polyallomer
ultratubes and gently mixed with polyethylene glycol-
6000 (Sigma/Fluka) and sodium chloride to final concen-
trations of 5% and 0.25 M, respectively. Reactions were
incubated at +4°C overnight, followed by centrifugation
for one hour at 15,000 ×g, +4°C, in an SW28 rotor, to
pellet the precipitated VLP. Pellets were gently resus-
p e n d e di n2 0m MT r i s ,p H 7 . 4 ,0 . 1MN a C l ,0 . 1m M
EDTA (TNE), or in 1X PBS, pH 7.4, overlayed on 20%
sucrose cushions, and centrifuged for 2 hours at 55,000
rpm, +4°C, in an SW60Ti rotor. Pellets were resuspended
in TNE or PBS and VLP were further purified on 20 -
60% discontinuous sucrose gradients, as described above
for sucrose cushions. VLP were removed from visible
bands throughout the gradient, combined, diluted in
TNE or PBS, and centrifuged for one hour at 15,000 ×g,
+4°C, in an SW28 rotor, to pellet the purified VLP and to
remove sucrose. Pellets were resuspended in TNE or PBS
and allowed to dissolve fully at 4°C overnight. VLP used
for immunizations were filtered through 0.45 μms y r i n g e
filters before being assayed for protein content by Micro
BCA. VLP preparations were stored at 4°C in TNE or
PBS at concentrations ranging from 200 - 3000 μg/mL.
VLP for immunizations were tested for endotoxin levels
with a high sensitivity Limulus Amebocyte Lysate (LAL)
test (Sigma-Aldrich).
Western blot and densitometry analyses
Expression of LASV GP1, GP2, NP, and Z-3’HIS in
VLP were confirmed by Western blot analysis using
anti-LASV mAbs L52-74-7A, L52-216-7, goat polyclo-
nal antibody (PAb) to E. coli generated nucleoprotein
and a-6X-HIS mAb, respectively. Secondary antibodies
were horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG (H+L) or rabbit anti goat IgG (H+L).
Five to ten μg of total VLP protein were denatured,
reduced, and resolved on 10% NuPAGE Novex Bis-Tris
gels, according to the manufacturer’s specifications
(Novex, San Diego, CA). Proteins were transferred to
0.45-μm nitrocellulose membranes, blocked, and
probed in 1X PBS, pH 7.4, 5% non-fat dry milk, 1%
heat inactivated fetal bovine serum, 0.05% Tween-20,
and 0.1% thymerosal. Membranes were then incubated
in LumiGlo chemiluminescent substrate (KPL) and
exposed to Kodak BioMax MS Film. Developed films
were subjected to high resolution scanning for densito-
metry analysis. Quantification of band intensity was
performed using National Institutes of Health ImageJ
1.41o software http://rsb.info.nih.gov/ij, and following
the procedure outlined in http://www.lukemiller.org/
journal/2007/08/quantifying-western-blots-without.
html, using TIFF files.
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HEK-293T/17 cell cytotoxicity induced by LASV Z,
GPC, and NP expression was monitored with a TACS
(tm) MTT Cell Proliferation Assay (R&D Systems, Min-
neapolis, MN), according to manufacturer’s instructions.
The transfection procedure was scaled down to a 96-
well format, with each condition analyzed in triplicate.
Data was plotted as mean absorbance at 562 nm, with
standard deviation, and background correction at
650 nm.
Protease protection assays
Pseudovirus-specific protein composition and VLP
structure were characterized by trypsin protection
assays. Ten μg of purified VLP were treated with 100
μg/mL trypsin in the presence or absence of 1% Triton
X-100, for 30 minutes, at room temperature. Reactions
were stopped by the addition of soybean trypsin inhibi-
tor to a final concentration of 3 mg/mL, addition of
SDS-PAGE buffer and reducing agent (DTT), and heat-
ing to 70°C for ten minutes. Proteins were resolved on
10% NuPage gels and detected by western blot, as
described above.
PNGase F, Endo H, and neuraminidase assays
The glycosylation patterns of LASV VLP GP1 and GP2
generated from expression of LASV Z+GPC+NP were
resolved by treatment with the deglycosidases PNGase
F, Endo H, and neuraminidase, as previously described
[12], on sucrose cushion purified VLP. Reactions were
performed on heat denatured VLP to conform to manu-
facturer’s recommendations for PNGase F and Endo H
digestion conditions, and on non-denatured VLP. Con-
trol reactions were similarly processed except that
enzymes were not added. Specificity of deglycosidases
was assessed by monitoring the effects of all three
enzymes on LASV NP and Z proteins packaged into
VLP. Proteins were subsequently resolved by reducing
SDS-PAGE, blotted, probed with a-LASV GP1, GP2, a-
6X-HIS mAbs, or goat PAb a-NP, and developed as
described above.
Lectin-based Glycan differentiation assays
Glycosylation patterns of VLP associated proteins were
characterized via binding of glycan-specific lectins using
aD I GG l y c a nD i f f e r e n t i a t i o nK i t( R o c h eA p p l i e d
Science, Mannheim, Germany), according to the manu-
facturer’s instructions. LASV VLP proteins were
resolved by reducing SDS-PAGE, blotted onto nitrocel-
lulose, and subjected to lectin binding assays.
RNA extraction from purified VLP
RNA was extracted from VLP with Trizol(tm) reagent/
chloroform and isopropanol precipitation, essentially
as outlined in the product insert (Invitrogen). RNA
pellets were washed with 75% ethanol, air dried, resus-
pended in DEPC-treated water, and quantitated by
A280. RNA was glyoxal-denatured and analyzed on
1.5% agarose gels containing ethidium bromide, essen-
tially as described in Sambrook et al. [66]. Gels were
photographed on a Kodak EDAS 120 system and
images were saved as TIFF files for densitometry ana-
lysis. Total RNA was extracted from corresponding
transfected HEK293T/17 cells using the same
procedure.
Genomic DNA fragmentation analysis
Genomic DNA was isolated from HEK-293T/17 cells
using a Qiagen DNeasy kit, according to the manufac-
turer’s instructions. Purified DNAs were quantitated by
A260/A280. Two μgs of each DNA sample were resolved
per lane of a 1.8% TAE/agarose gel containing 1 μg/mL
ethidium bromide. High resolution gel images were
converted to TIFF format for analysis.
Murine immunizations
Six to eight week-old female BALB/c mice were pur-
chased from Charles River Laboratories and housed
according to Tulane University’s IACUC guidelines.
Research was conducted in compliance with the Animal
Welfare Act and other Federal statutes and regulations
relating to animals and experiments involving animals
and adheres to principles stated in the Guide for the
Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was con-
ducted is fully accredited by the Association for Assess-
ment and Accreditation of
Laboratory Animal Care International. For immuni-
zations, mice were randomly divided into groups of 10
and injected intraperitoneally with 10 μgo fL A S VV L P
(Z+GPC or Z+GPC+NP) in 100 μL of sterile TNE.
Ten mice were similarly injected with 100 μLT N Ea s
vector control. One prime and two boosts were per-
formed, three weeks apart, each with 10 μg of homolo-
gous LASV VLP. Mice were sacrificed by CO2
asphyxiation three weeks after the last boost and
whole blood was collected by cardiac puncture. The
plasma fraction was isolated and frozen at -80°C until
analysis.
IgG and IgM ELISA on recombinant LASV proteins and
VLP
Murine immunoglobulin-g endpoint titers to whole VLP,
and IgG-g t oG P 1a n dG P 2w e r ed e t e r m i n e di ns e r i a l l y
diluted sera samples. Nunc MaxiSorp ELISA plates were
coated with 2 μg/mL total VLP protein in carbonate
buffer. Recombinant mammalian cell expressed LASV
GP1 and GP2, produced by Vybion, Inc., Ithaca, NY,
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blocked, and lyophilized by Corgenix Medical Corp.,
Broomfield, CO. Plates coated with VLP were blocked
in 1X PBS, pH 7.4, 5% NFDM, 1% FBSΔ, 0.05% Tween-
20, 0.01% thymerosal. The same buffer was used for all
sera and secondary antibody dilutions. Mouse IgG was
detected with a Horseradish Peroxidase (HRP)-labeled
goat F(ab’)2 anti-mouse IgG g-specific reagent at 1:2500
dilution (KPL). Reactions were developed with TMB for
15 minutes at room temperature, stopped with 0.5 N
H2SO4, and plates were read at 450 nm in a BioTek 808
ELISA reader. Viral antigen-specific IgG and IgM analy-
sis in the sera of convalescent patients was similarly per-
formed, with serum samples diluted 1:100 in NFDM
blocking reagent, and detected with HRP labelled goat F
(ab’)2 anti-human IgG, g or μ-specific reagents, respec-
tively. Monoclonal antibodies to GP2 and NP were used
as positive controls on antigen coated plates to verify
presence of relevant epitopes on viral proteins. Total
IgG fraction from naive mice was used as negative con-
trol antibody (ms IgG). Sera collected from North
American volunteer blood donors that had never tra-
velled to LHF endemic regions, and that were confirmed
naive to LASV antigens by ELISA were used as negative
controls. Serum from a patient that tested positive for
NP-specific IgM and IgG antibodies in a recombinant
NP ELISA was used as a positive control in these assays
(G652-3).
Electron microscopy
HEK-293T/17 cells were harvested at 72 hours post
transfection with LASV gene constructs. Cells were pel-
leted by centrifugation at 200 ×g, washed once in cold
(4°C) PBS, and fixed with 2.5% glutaraldehyde in phos-
phate buffer. Fixed cell pellets were embedded in 1%
agarose prepared in phosphate buffer and allowed to
solidify at 4°C. Cell pellets in agarose were post fixed
with 1% osmium tetroxide, dehydrated in a graded ser-
ies of ethanol, and embedded in epoxy resin. Thin sec-
tions were cut on a Leica UC6 ultramicrotome, stained
with uranyl acetate and lead citrate, followed by exami-
nation on a Hitachi H-7100 transmission electron
microscope.
Statistical analysis and in silico tools
Statistical analysis of data was performed with GraphPad
InStat, V3.06 (GraphPad Software, Inc., San Diego, CA),
using Analysis of Variance (ANOVA), paired or
unpaired Student’stt e s t ,a n dP e a r s o n ’sc o r r e l a t i o n .T h e
PeptideCutter analysis tool from the Swiss Institute of
Bioinformatics ExPASy Proteomics Server was employed
in the in silico analysis of predicted trypsin cleavage
sites on LASV GP1 and GP2.
Additional material
Additional file 1: Graphic representations of recombinant
constructs, mammalian plasmid vector, and single LASV gene
expression.A i. GPC gene with known domains (SP, signal peptide; GP1,
glycoprotein 1; GP2, glycoprotein 2; TM, transmembrane; IC, intracellular;
ER, endoplasmic reticulum retention signal). Signal peptidase (SPase) and
subtilase SKI-1/S1P cleavage sites are indicated. Seven glycosylation sites
on GP1 and 4 on GP2 are indicated by Y.A ii. GPC construct with C-
terminal FLAG. Aiii. Nucleoprotein gene displaying putative helicase, RNA
binding, WD40, repeated [R] domains, and pre-protein cleavage motif.
Aiv. NP with C-terminal 6X-HIS. Av. Z gene displaying myristoylation
(myr), cyclin/CDK, nuclear receptor box (NR BOX), RING, and late PTAP
and PPPY domains. Avi. Z gene with one glycine-6X-HIS domain inserted
at amino acid position +3. Avii. Z gene with C-terminal 6X-HIS. B.
Mammalian expression vector pcDNA3.1+_intA was used to generate all
expression constructs outlined in these studies. C. LASV NP-3’HIS (lane 1),
Z-3’HIS (lane 2), Z-5’glyHIS (lane 3), and GPC (lane 4) gene expression
were analyzed by western blot. Ci. Intracellular (C) expression of NP-3’HIS
(60 kDa), Z-3’HIS (12 kDa), Z-5’glyHIS (15 kDa), and GPC (72 kDa). In the
GPC lane, probed with an a-GP1 mAb, expression of monomeric GP1
was also detected (42 kDa). In culture supernatants (S), NP-3’HIS was not
detected (Cii, lane 1). Z-3’HIS was present in supernatants at high levels
(Cii, lane 2). Disrupting the myristoylation site on the N-terminus of Z
prevented the release of the protein from cells (Cii, lane 3). The soluble
GP1 component previously described through expression of GPC [11,12]
was detected in supernatants (42 kDa) (Cii, lane 4).
Additional file 2: Transfection experiments with combinations of
tagged and untagged Z, NP, and GPC constructs. HEK-293T/17 cells
were transfected in 6-well plates as outlined in Methods, with
combinations of LASV gene constructs. VLP were purified through 20%
sucrose cushions and subjected to western blot analysis. Blots were
probed with aGP1, aGP2, aFLAG M2, aHIS mAbs, or aNP PAb. Lane
designations: 1. Z; 2. Z-3’HIS; 3. Z+GPC+NP; 4. Z+GPC-FLAG+NP; 5. Z-3’HIS
+GPC+NP; 6. Z-3’HIS+GPC-FLAG+NP; 7. Z+GPC; 8. Z-3’HIS+GPC; 9. Z
+GPC-FLAG; 10. Z-3’HIS+GPC-FLAG; 11. Z+NP; 12. Z-3’HIS+NP. The Z-3’HIS
+GPC+NP combination consistently generated the highest VLP yields
with corresponding incorporation of all three LASV genes.
Additional file 3: DNA fragmentation and MTT cytotoxicity analysis
of HEK-293T/17 cells transfected with LASV gene constructs.A .
Fragmentation assays were performed by resolving 2 μg of genomic
DNA from transfected and untransfected cells on agarose gels. A low
molecular weight DNA laddering effect consistent with apoptotic DNA
fragmentation was not observed in any of the samples (n = 3). B. MTT
cytotoxicity analysis of transfected cells, in 96-well format (n = 3). Vector
only (pcDNA3.1+:intA), NP, GPC, and GPC-FLAG transfected cells did not
display significant cytotoxicity when compared to untransfected controls
(293T/17 cell ctrl) [p > 0.05]. Conversely, inclusion of the Z matrix gene,
in native (Z) or 3’HIS-tagged format (Z-3’HIS), alone or in combination
with any version of LASV GPC and/or NP resulted in significant reduction
in MTT incorporation levels [p < 0.05 to p < 0.001, n = 3]. The numbered
gel lanes in A. correspond to the bars in B. The p value for each
transfection condition compared to the 293T/17 cell control is shown
above the corresponding lane.
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